Literature DB >> 5031656

Pharmacodynamics of propranolol in renal failure.

F D Thompson, A M Joekes, D M Foulkes.   

Abstract

The pharmacodynamics of propranolol were studied in patients with renal functional impairment. (14)C-labelled propranolol was given either intravenously or by mouth and the disappearance rates of propranolol, 4-hydroxypropranolol, and total radioactive metabolites measured. The renal clearance of total radioactive compounds is directly related to renal function. The half-life of total radioactivity is greatly lengthened in the presence of severe renal failure while the half-lives of the pharmacologically active propranolol and 4-hydroxymetabolite are slightly reduced. There is a suggestion that the absorption of propranolol is delayed in renal failure. No known pharmacological action or side effects from the other metabolic products of propranolol have been recognized. There is still too little well-documented evidence concerning the beta-blocking activity of the unidentified major metabolites of propranolol to suggest any alteration in the dosage regimen used in renal failure.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5031656      PMCID: PMC1788019          DOI: 10.1136/bmj.2.5811.434

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  4 in total

1.  Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey.

Authors:  A Hayes; R G Cooper
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

2.  The metabolism of C14-ICI 54,450 (myalex) in various species--an in vivo NIH shift.

Authors:  D M Foulkes
Journal:  J Pharmacol Exp Ther       Date:  1970-03       Impact factor: 4.030

3.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04

4.  Controlled trial of propranolol in hypertension.

Authors:  F J Zacharias; K J Cowen
Journal:  Br Med J       Date:  1970-02-21
  4 in total
  18 in total

1.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

3.  Pharmacokinetics of practolol in renal failure.

Authors:  G Bodem; H Grieser; M Eichelbaum; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

4.  Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia.

Authors:  E E Ohnhaus; E Nüesch; J Meier; F Kalberer
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Pharmacokinetics of atenolol in relation to renal function.

Authors:  W Kirch; H Köhler; E Mutschler; M Schäfer
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

6.  Hypertrophic and hypoactive smooth endoplasmic reticulum in hepatocytes uremic patients. A morphometric and biochemical study.

Authors:  S Kawata; K Seki; Y Shinji; S Tarui; T Sugiyama; T Yamano
Journal:  Gastroenterol Jpn       Date:  1982

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Propranolol disposition in renal failure.

Authors:  A J Wood; R E Vestal; C L Spannuth; W J Stone; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

9.  Influence of renal failure on the hepatic clearance of bufuralol in man.

Authors:  L Balant; R J Francis; T N Tozer; A Marmy; J M Tschopp; J Fabre
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

10.  Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Authors:  B Flouvat; S Decourt; P Aubert; L Potaux; M Domart; A Goupil; A Baglin
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.